Investor Relations
Investor Relations
Myrexis, Inc., headquartered in New York, New York, is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments life sciences assets. In February 2012, the Company announced that it was shifting its strategic direction and suspended development activities of all its preclinical and clinical development programs in oncology and autoimmune diseases.
Recent Releases
Jan 23, 2013
Nov 9, 2012 |
|
||||||||||||||||||||||



